These clinical features in COVID-19 suggest that preexisting SARS-CoV-2–specific T-cell responses might be ineffective against infection with VOCs and imply that SARS-CoV-2, but more probably VOCs, can still escape from CD8+ T-cell immunity and lead to inactivation of T-cell immunity while maintaining active viral replication (80–83). This evidence concerns the gene CD8A and COVID-19.